Medical research is increasingly focusing on how existing medicines, licensed for use in one condition, can also be used to treat different conditions. Research is promising and indicates that there could be other diseases and patients that could benefit from the use of off-patent medicines. Promising areas include Parkinson’s.
Read more

Despite an urgent need for new medications, clinical trials in Parkinson's have a low rate of success. In this section we look at the barriers that interfere with the establishment of effective clinical trials and determine a means of addressing them...
Read more

By understanding what matters most to people with Parkinson's, we can shape our campaigns and influences to help create a better research environment so that newer, kinder and more effective treatments can reach patients sooner...
Read more

The more we know about how Parkinson’s (PD) progresses, the better we can tailor treatments to people with PD. Also, better measurement of symptoms means more efficient and less expensive ways of testing new treatments in clinical trials...
Read more

Latest

For some considerable time CPT has been interested in nerve growth factors or 'neurotrophic' factors for Parkinson's. GDNF, CDNF and C-CDNF are three interesting candidates and our research work within this field continues with drive and urgency.

Dr. Johnny Acheson is an Emergency Medical Consultant who is also living with Parkinson’s. Johnny has created sketches to fundraise and to educate about Parkinson’s and depict the humorous side of working in emergency medicine!

Over 50 cyclists, including Mike Tindall and Iain Balshaw, will set off independently on 28 June to tackle what would have been the toughest day on the 'Raid Alpine' ride - but instead, they'll be doing this around their local area!

Most read

In a major breakthrough for the treatment of Parkinson's, researchers working with laboratory rats show it is possible to make dopamine cells from embryonic stem cells and transplant them into the brain.

Our International Linked Clinical Trials initiative (iLCT) identifies potential new treatments to slow, stop or reverse Parkinson’s disease by 'repurposing' or repositioning drugs that are approved to treat other conditions.

The study, published in The Lancet and funded by The Michael J. Fox Foundation for Parkinson’s Research (MJFF), supported by CPT found that people with Parkinson’s treated with Exenatide for one year performed better in motor tests than those on placebo.

At this current time, we are working remotely and are unable to fulfill orders made via our online shop. We kindly ask that you refrain from purchasing items until normal working practices are resumed. Thank you for your patience. Please stay safe and well. From all at CPT.